HealthcareServices

Liquid Biopsy Market Anticipated to Record Steady Gains, Advancing to $3.11 Billion by 2030

February 26, 2026February 26, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the liquid biopsy market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Liquid Biopsy Market between 2026 and 2030?

The liquid biopsy market has observed swift growth over recent years. It is anticipated to expand from $1.46 billion in 2025 to $1.71 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.3%. This historical growth can be attributed to various factors such as the limitations associated with traditional tissue biopsy procedures, the rising global prevalence of cancer, the early adoption of blood-based diagnostics, ongoing advancements in molecular biology techniques, and an increased emphasis on the early detection of cancer.

The liquid biopsy market is projected to experience substantial expansion in the coming years. By 2030, this market is anticipated to reach $3.11 billion, exhibiting a compound annual growth rate (CAGR) of 16.2%. This growth during the forecast period can be attributed to factors such as increasing demand for precision oncology, wider adoption in routine cancer screening, broader applications in monitoring cancer recurrence, an uptick in oncology diagnostic expenditure, and greater awareness among healthcare professionals and patients. Key trends anticipated for the forecast period encompass a growing uptake of non-invasive cancer diagnostics, expanded utilization of liquid biopsy for early cancer identification, increased need for real-time treatment tracking, the spread of liquid biopsy within personalized oncology, and its rising clinical recognition as a viable substitute for tissue biopsy.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2815&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Liquid Biopsy Market?

A primary factor propelling the expansion of the liquid biopsy market is the surge in government investment towards enhancing cancer detection methods. This financial support for improving cancer detection stems largely from the escalating worldwide prevalence of cancer, the imperative for timely diagnosis to achieve better treatment results, and an emphasis on lowering healthcare expenditures via cutting-edge diagnostic innovations. Such governmental backing aids liquid biopsy by expediting its research and development, providing assistance for clinical trials, and fostering the widespread acceptance of sophisticated, non-invasive diagnostic tools, thereby advancing early cancer identification and tailored treatment approaches. As an illustration, in October 2024, the UK government website, gov.UK, reported an allocation of £118 ($150.38) million to UK Research and Innovation, comprising £54 million from the government itself and £64 ($81.55) million contributed by partners. Consequently, the heightened government funding dedicated to advancing cancer detection is a significant driver for the growth of the liquid biopsy market.

What Segments Are Included Within The Liquid Biopsy Market?

The liquid biopsy market covered in this report is segmented –

1) By Product: Assay Kits, Instruments, Services

2) By Clinical Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring

3) By End User: Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers

Subsegments:

1) By Assay Kits: cfDNA Assays, ctDNA Assays, Exosome-based Assays, RNA-based Assays

2) By Instruments: PCR Instruments, Next-Generation Sequencing (NGS) Instruments, Microarray Instruments

3) By Services: Testing Services, Data Analysis Services, Laboratory Services

What Trends Are Projected To Support The Growth Of The Liquid Biopsy Market?

Leading companies within the liquid biopsy market are concentrating on developing advanced solutions, such as all-encompassing circulating tumor DNA (ctDNA) genomic-profiling assays. These innovations aim to speed up noninvasive cancer analysis, facilitate quicker treatment decisions, and expand access to personalized oncology, especially in cases where tissue samples are scarce or cannot be obtained. A comprehensive ctDNA genomic-profiling assay examines tumor-derived cell-free DNA fragments found in the bloodstream. It identifies somatic small variants, copy-number alterations, insertions/deletions, and key immuno-oncology markers (e.g., bTMB and bMSI). This method provides a more extensive understanding of tumors, bypassing the invasive nature, potential sampling errors, and extended processing times associated with conventional tissue biopsies. For instance, in November 2023, Illumina Inc., a US–based sequencing and genomics firm, introduced TruSight Oncology 500 ctDNA v2. This research-focused liquid biopsy panel facilitates noninvasive genomic profiling of solid tumors, featuring an enhanced hybrid-capture panel combined with DRAGEN bioinformatics to sequence 523 biomarkers from minimal cfDNA input. This assay efficiently enriches and detects SVs, CNVs, indels, and immuno-oncology metrics, demonstrating strong analytical performance. It provides simplified workflows, requiring only a single hybridization step and boasting a turnaround time of less than 4 days, while also being compatible with NovaSeq systems and future automation advancements. The solution proves valuable when tissue samples are unobtainable or delayed, complementing existing tissue testing. It also enables extensive pan-cancer research and trial screening, delivering quicker insights, accommodating low-input samples, and promoting simpler integration across various laboratory settings.

Who Are The Prominent Global Companies Shaping The Liquid Biopsy Market Landscape?

Major companies operating in the liquid biopsy market are QIAGEN NV, Roche Diagnostics Ltd., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific Inc., Biocept Inc., Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Quantum Biosystems Inc., Menarini Silicon Biosystems Inc., Pathway Genomics Corporation, Sysmex Corporation, Janssen Global Services LLC, Natera Inc., ANGLE Plc, Bio Techne Corp, Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corporation, Epic Sciences Inc., Exosome Diagnostics Inc., GRAIL Inc., Inivata Ltd., NIPD Genetics, Oncocyte Corporation, Personal Genome Diagnostics Inc., RainDance Technologies Inc., Thrive Earlier Detection Corp.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Which Region Is Projected To Lead The Liquid Biopsy Market During The Forecast Period?

North America was the largest region in the liquid biopsy market in 2025. Western Europe was the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Liquid Biopsy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2815&type=smp

Browse Through More Reports Similar to the Global Liquid Biopsy Market 2026, By The Business Research Company

Biopsy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Liquid Biopsy For Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

Biopsy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795